MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate Development of Cell Therapies for Genetic Diseases Page 1

Kamau will use MaxCyte’s Flow Electroporation technology and ExPERT platform to support its novel homology-directed repair (HDR) gene correction technology

ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell technology company providing platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapies and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage gene correction for stem cell therapy company, today announced that they have entered into a strategic platform license agreement (SPL).